Google
Trusted Resources: News & Events
Latest announcements and gatherings
New Research Suggests SANGUINATE™ Reduces the Number of Sickled Red Blood Cells in Patients with Vaso-Occlusive Crisis
SANGUINATE™, the only investigational biopharmaceutical product currently in clinical development for the treatment of multiple comorbidities of sickle cell disease (SCD), is effective in returning red blood cells to a more normal morphology (shape) in patients experiencing vaso-occlusive crisis (VOC) related to SCD, according to research presented at the 11th Annual Symposium of the Foundation for Sickle Cell Disease Research (FSCDR) in Fort Lauderdale, Fla.
+myBinderRelated Content
-
Sickle cell patients in UK survey, especially those 16 to 20, voice problems with care and pain relief givenIn a survey, patients across the...
-
Prostacyclin-analog therapy in sickle cell pulmonary hypertensionSickle cell disease (SCD) is associated ...
-
Birth Weights in Sickle Cell Disease Pregnancies: A Cohort StudyPregnancy in women with Sickle Cell Dise...
-
FDA Awards UNC Researcher $2M Grant to Study Kidney Disease in Sickle Cell AnemiaThe U.S. Food and Drug Administration (F...
-
Successful Gene Therapy for Sickle Cell DiseasePrior to this report, the only curative ...
-
Stem cell gene-editing method may be breakthrough for sickle cell researchResearchers have cured mice with a genet...
-
More Cures for More Patients Through Sickle Cell Research: Courtney Fitzhugh, MDhttps://www.youtube.com/watch?v=OvdpT1Dn...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.